Alzheimer's Disease is a new Decision Resources study that identifies and evaluates emerging therapies and treatment trends that will have a significant influence on this market over a 2000-2010 study period.

  (Photo:  http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )    AChEIs Leave Room for Improvement 

The first Alzheimer's disease (AD) therapies that show evidence of delaying disease symptom progression are acetylcholinesterase inhibitors (AChEIs). They are thus the preferred therapy for AD treatment and will continue to dominate the AD market throughout our 2000-2010 study period. However, AChEIs are not effective for all AD patients. This lack of universal efficacy, coupled with the inability of AChEIs to completely halt disease progression or profoundly restore function to AD patients, represents the area of greatest unmet need-and greatest opportunity-in the treatment of AD.

Market Opportunities-Disease-Modifying Therapies, Diagnostics Several drug developers are working on approaches to satisfy the large unmet need for disease-modifying therapies. However, therapies that are effective in treating psychomotor agitation, especially wandering, are also needed. Nonpharmacologically, more efficient means of early and reliable diagnosis is a major unmet need; no diagnostic tests in development thus far have proved specific and sensitive enough to address this need.

Market Will More than Double by 2010

The market for agents used to treat AD totaled more than $660 million in 2000. During the course of our forecast period, factors influencing pharmaceutical sales will include the following: Increased recognition, diagnosis, and treatment of AD. A rise in the number of prevalent cases of AD as the general population ages. An increase in use of AChEIs for severe cases of AD. The introduction of new therapies (e.g., additional AChEIs, other noncholinergic neurotransmitter modulators, and a nerve growth factor [NGF] agonist) and the increased use of adjuvant therapies.

Overall sales should more than double to exceed $1.6 billion in 2010.

Alzheimer's Disease offers invaluable market intelligence for pharmaceutical companies competing in this market and is a part of Cognos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

Contact Frank Sama, 781.296.2553 (tel), 781.296.2525 (fax), or sama@dresources.com.

In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or fbidart@decisionresources.be.

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X98211632

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, +1-781-296-2553,
sama@dresources.com

Decision Resources Study Evaluates New Entries to the Market for Depression

View Now